Citation Report

List of articles citing

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA induces homology-directed DNA repair

DOI: 10.1038/s41551-017-0137-2
Nature Biomedical Engineering, 2017, 1, 889-901.

#	Paper	IF	Citations
494	Nanoparticles for CRISPR-Cas9 delivery. *Nature Biomedical Engineering*, **2017**, 1, 854-855	19	39
493	Gene therapy for children with AADC deficiency. **2017**, 1, 250-251		1
492	Recent developments in intracellular protein delivery. **2018**, 52, 25-31		44
491	Nanoparticle-Mediated Delivery towards Advancing Plant Genetic Engineering. **2018**, 36, 882-897		194
490	Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. **2018**, 171, 207-218		180
489	Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. **2018**, 140, 6596-6603		89
488	Innovations in CRISPR technology. **2018**, 52, 95-101		14
487	Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. *Journal of Controlled Release*, **2018**, 274, 24-34	11.7	89
486	Personalised genome editing - The future for corneal dystrophies. **2018**, 65, 147-165		28
485	Engineering the Delivery System for CRISPR-Based Genome Editing. **2018**, 36, 173-185		170
484	Combinatorial library of chalcogen-containing lipidoids for intracellular delivery of genome-editing proteins. **2018**, 178, 652-662		45
483	The Promise and Challenge of In Vivo Delivery for Genome Therapeutics. **2018**, 13, 376-382		40
482	ReGene: Blockchain backup of genome data and restoration of pre-engineered expressed phenotype. **2018**,		4
481	Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy. **2018**, 8,		32
480	CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. **2018**, 6,		50
479	A plug and play approach for the decoration of nanoparticles with recombinant proteins. **2018**, 13, 2547-2550		2
478	Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy. **2019**, 20, 634-643		29

477	Engineering CRISPR-Cas9 RNA-Protein Complexes for Improved Function and Delivery. **2018**, 1, 367-378		6
476	Double-Stranded Biotinylated Donor Enhances Homology-Directed Repair in Combination with Cas9 Monoavidin in Mammalian Cells. **2018**, 1, 414-430		8
475	High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. **2018**, 115, E9944-E9952		103
474	Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. **2018**, 9, 4092		80
473	Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics. **2018**, 20, 108		48
472	A peptide delivery system sneaks CRISPR into cells. **2018**, 293, 17306-17307		8
471	Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors. *Journal of Controlled Release*, **2018**, 291, 90-98	11.7	20
470	CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 () in adipose cells to enhance energy expenditure. **2018**, 293, 17291-17305		24
469	Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery. *ACS Applied Materials & Interfaces*, **2018**, 10, 31915-31927	9.5	33
468	All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. **2018**, 19, 137		58
467	Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. **2018**, 15, 905-913		54
466	CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo. *Molecular Therapy*, **2018**, 26, 2604-2616	11.7	39
465	Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation. **2018**, 10, 1179573518787469		6
464	Debugging the genetic code: non-viral delivery of therapeutic genome editing technologies. **2018**, 7, 24-32		6
463	Manufacturing and Delivering Genome-Editing Proteins. **2018**, 1867, 253-273		2
462	CRISPR-Cas guides the future of genetic engineering. **2018**, 361, 866-869		606
461	Delivering CRISPR: a review of the challenges and approaches. **2018**, 25, 1234-1257		452
460	Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms. **2018**,		22

459	Modular Protein Engineering Approach to the Functionalization of Gold Nanoparticles for Use in Clinical Diagnostics. **2018**, 1, 3590-3599		6
458	Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing. **2018**, 130, 10425-10429		26
457	Block Copolymer Micelles in Nanomedicine Applications. **2018**, 118, 6844-6892		608
456	Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing. **2018**, 57, 10268-10272		106
455	Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. *Nature Biomedical Engineering*, **2018**, 2, 497-507	19	180
454	CRISPR-Cas9 therapies in experimental mouse models of cancer. **2018**, 14, 2083-2095		4
453	Personalized gene and cell therapy for Duchenne Muscular Dystrophy. **2018**, 28, 803-824		27
452	65 YEARS OF THE DOUBLE HELIX: The advancements of gene editing and potential application to hereditary cancer. **2018**, 25, T141-T158		1
451	Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies. **2018**, 10,		55
450	Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair. **2018**, 7,		88
449	Rescued from the fate of neurological disorder. *Nature Biomedical Engineering*, **2018**, 2, 469-470	19	3
448	Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivo. **2018**, 9, 3313		51
447	Emerging Strategies for Genome Editing in the Brain. **2018**, 24, 822-824		1
446	Transgenic Mouse Models in Cancer Research. **2018**, 8, 268		87
445	Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines. **2018**, 9, 2283		32
444	Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection. **2018**, 4, 499-512		55
443	Gene Editing on Center Stage. **2018**, 34, 600-611		65
442	Genome editing by natural and engineered CRISPR-associated nucleases. **2018**, 14, 642-651		71

441	Realizing the Dream. **2018**, 1, 217-218		
440	Straightforward Delivery of Linearized Double-Stranded DNA Encoding sgRNA and Donor DNA for the Generation of Single Nucleotide Variants Based on the CRISPR/Cas9 System. **2018**, 7, 1651-1659		1
439	Nanotechnology approaches to eradicating HIV reservoirs. **2019**, 138, 48-63		21
438	Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles. *Biomaterials Science*, **2019**, 7, 596-606	7.4	49
437	CRISPR for Neuromuscular Disorders: Gene Editing and Beyond. **2019**, 34, 341-353		9
436	Application and Development of CRISPR/Cas9 Technology in Pig Research. **2019**,		3
435	Triple-Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases. **2019**, 131, 12534-12538		18
434	In situ biosynthesized gold nanoclusters inhibiting cancer development via the PI3K-AKT signaling pathway. **2019**, 7, 5336-5344		9
433	Triple-Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases. **2019**, 58, 12404-12408		37
432	Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9. **2019**, 158, 63-69		26
431	Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS. **2019**, 7,		5
430	CRISPR-Cas9 system: A new-fangled dawn in gene editing. **2019**, 232, 116636		62
429	Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect. **2019**, 12, 2437-2450		24
428	Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?. **2019**, 20, 3333-3339		12
427	A Self-Assembled Platform Based on Branched DNA for sgRNA/Cas9/Antisense Delivery. **2019**, 141, 19032-19037		33
426	An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles. **2019**, 10, 5012		30
425	Rational Design of Nanocarriers for Intracellular Protein Delivery. **2019**, 31, e1902791		80
424	Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia. **2019**, 10, 4906		44

423	Lipopeptide-Based Nanosome-Mediated Delivery of Hyperaccurate CRISPR/Cas9 Ribonucleoprotein for Gene Editing. **2019**, 15, e1903172		4
422	Gold Nanocluster-Mediated Efficient Delivery of Cas9 Protein through pH-Induced Assembly-Disassembly for Inactivation of Virus Oncogenes. *ACS Applied Materials & Interfaces*, **2019**, 11, 34717-34724	9.5	41
421	In Vivo Editing of Macrophages through Systemic Delivery of CRISPR-Cas9-Ribonucleoprotein-Nanoparticle Nanoassemblies. **2019**, 2, 1900041		16
420	Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited]. **2019**, 10, 3152-3182		30
419	Engineered materials for in vivo delivery of genome-editing machinery. **2019**, 4, 726-737		73
418	Ultrasensitive Multi-Species Detection of CRISPR-Cas9 by a Portable Centrifugal Microfluidic Platform. **2019**, 11, 559-565		15
417	Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations. **2019**, 18, 1124-1132		67
416	Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. **2019**, 31, e1902575		140
415	RNA delivery biomaterials for the treatment of genetic and rare diseases. **2019**, 217, 119291		23
414	Delivery of CRISPR/Cas9 for therapeutic genome editing. **2019**, 21, e3107		62
413	Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. **2019**, 10, 7718-7727		25
412	Cas9 Ribonucleoprotein Complex Delivery: Methods and Applications for Neuroinflammation. **2019** , 14, 565-577		4
411	Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers. **2019**, 9, 3280-3292		55
410	Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection. **2019**, 141, 111361		14
409	Polyrotaxane Nanocarriers Can Deliver CRISPR/Cas9 Plasmid to Dystrophic Muscle Cells to Successfully Edit the DMD Gene. **2019**, 2, 1900061		8
408	A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. **2019**, 5, eaaw8922		176
407	Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. **2019**, 8, 4254-4264		41
406	Genome editing for blood disorders: state of the art and recent advances. **2019**, 3, 289-299		4

405	Therapeutic application of the CRISPR system: current issues and new prospects. **2019**, 138, 563-590		13
404	Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems. **2019**, 41, 871-877		9
403	CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool. **2019**, 370, 725-735		16
402	Nanotechnology in Plant Science: To Make a Long Story Short. *Frontiers in Bioengineering and Biotechnology*, **2019**, 7, 120	5.8	133
401	B cells engineered to express pathogen-specific antibodies protect against infection. **2019**, 4,		42
400	Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing. **2019**, 52, 1555-1564		112
399	Recent advances in neuroepigenetic editing. **2019**, 59, 26-33		11
398	CRISPR/Cas9 Delivery Mediated with Hydroxyl-Rich Nanosystems for Gene Editing in Aorta. **2019**, 6, 1900386		14
397	Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. **2019**, 143, 68-96		244
396	Genome Editing for Duchenne Muscular Dystrophy. **2019**, 383-403		1
395	Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases. **2019**, 88, 191-220		69
394	Chitosan for gene delivery: Methods for improvement and applications. **2019**, 268, 25-38		72
393	Advances in CRISPR/Cas9 Technology for in Vivo Translation. **2019**, 42, 304-311		3
392	CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool. **2019**, 8,		20
391	Detection of unamplified target genes via CRISPR-Cas9 immobilized on a graphene field-effect transistor. *Nature Biomedical Engineering*, **2019**, 3, 427-437	19	236
390	Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein. **2019**, 55, 4707-4710		35
389	Natural Polyphenols Augment Cytosolic Protein Delivery by a Functional Polymer. *Chemistry of Materials*, **2019**, 31, 1956-1965	9.6	56
388	Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. *Molecular Therapy*, **2019**, 27, 710-728	11.7	354

387	Nonviral Gene Therapy: Design and Application of Inorganic Nanoplexes. **2019**, 365-390		1
386	CRISPR-mediated gene editing for the surgeon scientist. **2019**, 166, 129-137		4
385	Targeted Therapeutic Genome Engineering: Opportunities and Bottlenecks in Medical Translation. **2019**, 1-34		
384	Tunable nonenzymatic degradability of -substituted polyaspartamide main chain by amine protonation and alkyl spacer length in side chains for enhanced messenger RNA transfection efficiency. **2019**, 20, 105-115		9
383	CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review. **2019**, 14, e0212198		19
382	Biomaterials as vectors for the delivery of CRISPR-Cas9. *Biomaterials Science*, **2019**, 7, 1240-1261	7.4	52
381	Generation of CRISPR-Cas9 Complexes with Covalently Bound Repair Templates for Genome Editing in Mammalian Cells. **2019**, 9,		8
380	Application of nanoparticle-based siRNA and CRISPR/Cas9 delivery systems in gene-targeted therapy. **2019**, 14, 511-514		10
379	Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery. **2019**, 2, 1800085		15
378	Systems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing. **2019**, 45, 431-437		7
377	Delivery of gene therapy to resting immune cells for an HIV cure. **2019**, 14, 129-136		4
376	Carboxylated branched poly(β-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. **2019**, 5, eaay3255		68
375	Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes. **2019**, 11, 21317-21323		24
374	Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation. **2019**, 47, e13		39
373	The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery. *Bioconjugate Chemistry*, **2019**, 30, 263-272	6.3	205
372	Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook. **2019**, 26, 40-66		58
371	Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo. **2019**, 6, 1801423		78
370	CRISPR Correction of Duchenne Muscular Dystrophy. **2019**, 70, 239-255		78

369	New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine. **2019**, 37, 604-617	15
368	Nanotechnology-Based Approaches for Combating Tuberculosis: A Review. **2019**, 3, 130-139	1
367	Non-Viral Delivery To Enable Genome Editing. **2019**, 37, 281-293	62
366	CRISPR/Cas9 for cancer research and therapy. **2019**, 55, 106-119	112
365	Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing. **2019**, 40, e1800068	46
364	Genome editing in animals: an overview. **2020**, 75-104	1
363	Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications. **2020**, 36, 17-29	6
362	Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. **2020**, 72, 855-871	42
361	Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. **2020**, 5, 1	579
360	Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. **2020**, 23, 100789	58
359	Lipofection-mediated genome editing using DNA-free delivery of the Cas9/gRNA ribonucleoprotein into plant cells. **2020**, 39, 245-257	35
358	In situ self-assembling Au-DNA complexes for targeted cancer bioimaging and inhibition. **2020**, 117, 308-316	29
357	A neuroscientist's guide to transgenic mice and other genetic tools. **2020**, 108, 732-748	29
356	Strategies for the CRISPR-Based Therapeutics. **2020**, 41, 55-65	28
355	Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges. **2020**, 19, 215-228	3
354	Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. **2020**, 12, e1609	47
353	Base editing: advances and therapeutic opportunities. **2020**, 19, 839-859	60
352	Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. **2020**, 156, 80-118	81

351	Accessing Intracellular Targets through Nanocarrier-Mediated Cytosolic Protein Delivery. **2020**, 41, 743-754		10
350	InVivo Cancer-Based Functional Genomics. **2020**, 6, 1002-1017		3
349	Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing. **2020**, 12, 21001-21014		10
348	A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver. **2020**, 32, e2003537		23
347	Henceforth CRISPR. *Nature Biomedical Engineering*, **2020**, 4, 1023	19	1
346	Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for CRISPR/Cas-Based Genome Editing. **2020**, 14, 9243-9262		27
345	Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease. **2020**, 11, 731		6
344	Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach. **2020**, 18, 131-144		6
343	Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies. **2020**, 226, 71-82		3
342	Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects. **2020**, 6, eabb4005		45
341	Genome Editing for CNS Disorders. *Frontiers in Neuroscience*, **2020**, 14, 579062	5.1	5
340	Advances of Nanoparticles for Leukemia Treatment. **2020**, 6, 6478-6489		4
339	Nanomaterials for Therapeutic RNA Delivery. **2020**, 3, 1948-1975		26
338	Efficient Polymer-Mediated Delivery of Gene-Editing Ribonucleoprotein Payloads through Combinatorial Design, Parallelized Experimentation, and Machine Learning. **2020**,		22
337	Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1. *Molecular Therapy*, **2020**, 28, 2527-2539	11.7	6
336	Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using "Good-Fit" Genome-Editing Tools. *Cells*, **2020**, 9,	7.9	1
335	Spatial and Temporal Control of CRISPR-Cas9-Mediated Gene Editing Delivered via a Light-Triggered Liposome System. *ACS Applied Materials & Interfaces*, **2020**, 12, 52433-52444	9.5	12
334	Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods. **2020**, 258, 120282		33

333	Gold Nanoparticles for Vectorization of Nucleic Acids for Cancer Therapeutics. **2020**, 25,		8
332	Advances in oligonucleotide drug delivery. **2020**, 19, 673-694		407
331	Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. **2020**, 11,		32
330	Sequential Self-Assembly Using Tannic Acid and Phenylboronic Acid-Modified Copolymers for Potential Protein Delivery. **2020**, 21, 3826-3835		6
329	Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy. **2020**, 19, 320-329		17
328	Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies. **2020**, 6,		14
327	Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
326	CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. **2020**, 20, 456		2
325	Non-viral Gene Disruption by CRISPR/Cas9 Delivery Using Cell-permeable and Protein-stabilizing 30Kc19 Protein. **2020**, 25, 724-733		2
324	Translating CRISPR-Cas Therapeutics: Approaches and Challenges. **2020**, 3, 253-275		8
323	I-I Endonuclease-Mediated Plant Genome Editing by Protein Transport through a Bacterial Type III Secretion System. **2020**, 9,		1
322	Noncovalent Stabilization of Vesicular Polyion Complexes with Chemically Modified/Single-Stranded Oligonucleotides and PEG--guanidinylated Polypeptides for Intracavity Encapsulation of Effector Enzymes Aimed at Cooperative Gene Knockdown. **2020**, 21, 4365-4376		9
321	How can nanotechnology help to combat COVID-19? Opportunities and urgent need. **2020**, 18, 125		91
320	Treating Cystic Fibrosis with mRNA and CRISPR. **2020**, 31, 940-955		11
319	Delivery of Cas13a/crRNA by self-degradable black phosphorus nanosheets to specifically inhibit Mcl-1 for breast cancer therapy. **2020**, 8, 11096-11106		8
318	CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids. **2020**, 27, 705-731		29
317	Mutation-Directed Therapeutics for Neurofibromatosis Type I. **2020**, 20, 739-753		8
316	Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles. **2020**, 59, 14957-14964		23

315	A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing. **2020**, 10, 5532-5549		45
314	CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation. **2020**, 6, eaba2983		46
313	Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles. **2020**, 132, 15067-15074		5
312	Nanomaterials for gene delivery and editing in plants: Challenges and future perspective. **2020**, 135-153		1
311	Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system. *Nano Today*, **2020**, 34, 100895	17.9	22
310	PH-Responsive, Cell-Penetrating, Core/Shell Magnetite/Silver Nanoparticles for the Delivery of Plasmids: Preparation, Characterization, and Preliminary Evaluation. *Pharmaceutics*, **2020**, 12,	6.4	11
309	Recent Advances in CRISPR/Cas9 Delivery Strategies. **2020**, 10,		53
308	Mapping Fluorescence Enhancement of Plasmonic Nanorod Coupled Dye Molecules. **2020**, 10,		4
307	In Vivo Genome Engineering for the Treatment of Muscular Dystrophies. **2020**, 6, 52-66		
306	Biomaterials for gene editing therapeutics. **2020**, 187-231		
305	Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy. *Journal of Controlled Release*, **2020**, 322, 236-247	11.7	45
304	Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. **2020**, 98, 615-632		31
303	MicroRNA-125a-Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Restoring Effector/Regulatory T Cells Balance. **2020**, 14, 4414-4429		25
302	Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing. **2020**, 10, 4619		33
301	Gene editing and central nervous system regeneration. **2020**, 399-433		
300	Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. **2020**, 156, 188-213		62
299	Sweat gland regeneration: Current strategies and future opportunities. **2020**, 255, 120201		4
298	The delivery challenge: fulfilling the promise of therapeutic genome editing. **2020**, 38, 845-855		69

297	Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. **2020**, 11, 3232		132
296	Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion. **2020**, 20, 661-672		17
295	Engineered biomaterials for in situ tissue regeneration. **2020**, 5, 686-705		157
294	Genome editing methods in animal models. **2020**, 24, 8-16		15
293	Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer. **2020**, 7, 1903164		12
292	Lipid-Modified Aminoglycosides for mRNA Delivery to the Liver. *Advanced Healthcare Materials*, **2020**, 9, e1901487	10.1	12
291	Direct Cytosolic Delivery of Proteins through Coengineering of Proteins and Polymeric Delivery Vehicles. **2020**, 142, 4349-4355		53
290	The promise and challenge of therapeutic genome editing. **2020**, 578, 229-236		252
289	Delivery of Cas9/sgRNA Ribonucleoprotein Complexes via Hydroxystearyl Oligoamino Amides. *Bioconjugate Chemistry*, **2020**, 31, 729-742	6.3	11
288	Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid. **2020**, 18, 16		24
287	Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	9
286	Enabling Technologies for Personalized and Precision Medicine. **2020**, 38, 497-518		71
285	Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy. **2020**, 15, e0228072		12
284	Cell-Type-Specific CRISPR/Cas9 Delivery by Biomimetic Metal Organic Frameworks. **2020**, 142, 1715-1720		79
283	Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 323	5.8	9
282	[CRISPR-Cas9 for muscle dystrophies]. **2020**, 36, 358-366		
281	Gene delivery into cells and tissues. **2020**, 519-554		2
280	Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine. **2020**, 7, 1902552		5

279	Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein. *ACS Applied Materials & Interfaces*, **2020**, 12, 21386-21397	9.5	12
278	Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis. **2020**, 7, 1903432		17
277	Genome and base editing for genetic hearing loss. **2020**, 394, 107958		10
276	Engineered Interactions with Mesoporous Silica Facilitate Intracellular Delivery of Proteins and Gene Editing. **2020**, 20, 4014-4021		26
275	Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing. **2021**, 168, 55-78		20
274	Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes. **2021**, 23, 542-558		12
273	Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy. **2021**, 8, 146-156		10
272	Nanoplatforms for mRNA Therapeutics. **2021**, 4, 2000099		22
271	Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors. **2021**, 13, e1657		12
270	Non-viral strategies for delivering genome editing enzymes. **2021**, 168, 99-117		20
269	Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. **2021**, 39, 692-705		19
268	Revisiting gene delivery to the brain: silencing and editing. *Biomaterials Science*, **2021**, 9, 1065-1087	7.4	5
267	Delivery technologies for in utero gene therapy. **2021**, 169, 51-62		7
266	Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. **2021**, 11, 614-648		66
265	Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition. *Journal of Controlled Release*, **2021**, 330, 61-71	11.7	21
264	Binding-Mediated Formation of Ribonucleoprotein Corona for Efficient Delivery and Control of CRISPR/Cas9. **2021**, 60, 11104-11109		8
263	Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing. **2021**, 168, 246-258		12
262	Rational designs of in vivo CRISPR-Cas delivery systems. **2021**, 168, 3-29		58

261	Using Synthetically Engineered Guide RNAs to Enhance CRISPR Genome Editing Systems in Mammalian Cells. *Frontiers in Genome Editing*, **2020**, 2, 617910	2.5	4
260	CRISPR-Cas systems: Challenges and future prospects. **2021**, 180, 141-151		7
259	CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. **2021**, 181, 185-229		2
258	CRISPR genome engineering for retinal diseases. **2021**, 182, 29-79		5
257	CRISPR-Cas9 in cancer therapeutics. **2021**, 181, 129-163		1
256	Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect. **2021**, 78, 2683-2708		14
255	Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. *Nature Biomedical Engineering*, **2021**, 5, 144-156	19	26
254	Inorganic smart nanoparticles: a new tool to deliver CRISPR systems into plant cells. **2021**, 661-686		
253	Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing. **2021**, 21, 1049-1061		2
252	Harnessing lipid nanoparticles for efficient CRISPR delivery. *Biomaterials Science*, **2021**, 9, 6001-6011	7.4	10
251	Selecting a Cell Engineering Methodology During Cell Therapy Product Development. **2021**, 30, 9636897211003022		3
250	Challenges and Future Perspective of CRISPR/Cas Technology for Crop Improvement. **2021**, 289-306		1
249	Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for Hemoglobinopathies. **2021**, 28, 191-208		4
248	Evolving AAV-delivered therapeutics towards ultimate cures. **2021**, 99, 593-617		9
247	CRISPR Takes the Front Seat in CART-Cell Development. **2021**, 35, 113-124		6
246	Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. *Pharmaceutics*, **2021**, 13,	6.4	6
245	CRISPR/Cas technology as a promising weapon to combat viral infections. **2021**, 43, e2000315		9
244	Expanding the Potential of Mammalian Genome Engineering Targeted DNA Integration. **2021**, 10, 429-446		1

243	CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. *Molecular Therapy*, **2021**, 29, 571-586	11.7	37
242	The CRISPR revolution and its potential impact on global health security. **2021**, 115, 80-92		4
241	Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy. **2021**, 29, 1369-1376		11
240	Artificial Bioaugmentation of Biomacromolecules and Living Organisms for Biomedical Applications. **2021**, 15, 3900-3926		6
239	CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. **2021**, 8, 649896		14
238	Binding-Mediated Formation of Ribonucleoprotein Corona for Efficient Delivery and Control of CRISPR/Cas9. **2021**, 133, 11204-11209		
237	Magnetically Navigated Protein Transduction In Vivo using Iron Oxide-Nanogel Chaperone Hybrid. *Advanced Healthcare Materials*, **2021**, 10, e2001988	10.1	1
236	CRISPR/Cas-Dependent and Nuclease-Free Therapeutic Gene Editing. **2021**, 32, 275-293		8
235	CRISPR ribonucleoprotein-mediated genetic engineering in plants. **2021**, 2, 100168		19
234	Regulation of Proteins to the Cytosol Using Delivery Systems with Engineered Polymer Architecture. **2021**, 143, 4758-4765		11
233	Nanotechnology to advance CRISPR-Cas genetic engineering of plants. **2021**, 16, 243-250		36
232	Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies. *Frontiers in Genome Editing*, **2021**, 3, 630600	2.5	4
231	Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain. *Journal of Controlled Release*, **2021**, 332, 260-268	11.7	22
230	New insights on CRISPR/Cas9-based therapy for breast Cancer. **2021**, 43, 15		0
229	Frontiers of CRISPR-Cas9 for Cancer Research and Therapy. **2021**, 000, 000-000		1
228	gEL DNA: A Cloning- and Polymerase Chain Reaction-Free Method for CRISPR-Based Multiplexed Genome Editing. **2021**,		1
227	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. **2021**, 11, 639108		2
226	Toward the correction of muscular dystrophy by gene editing. **2021**, 118,		6

225	Nanotechnologies for Intracellular Protein Delivery: Recent Progress in Inorganic and Organic Nanocarriers. **2021**, 4, 2100009		5
224	Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science. **2021**, 23, 493-516		3
223	Endophytic Nanotechnology: An Approach to Study Scope and Potential Applications. **2021**, 9, 613343		17
222	Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. **2021**, 67, 103354		6
221	Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR/Cas9-mediated targeting of a major viral latent protein. **2021**, 93, 5065-5075		2
220	Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing. **2021**, 12, 673286		27
219	Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector. **2021**, 272, 120793		5
218	Phenylboronic acid modified carbon dots for improved protein delivery. **2021**, 237, 116586		1
217	All-In-One Dendrimer-Based Lipid Nanoparticles Enable Precise HDR-Mediated Gene Editing In Vivo. **2021**, 33, e2006619		16
216	Supramolecular Nanosubstrate-Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion. **2021**, 17, e2100546		1
215	Therapeutic Genome Editing and In Vivo Delivery. **2021**, 23, 80		
214	New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape. *Molecular Therapy*, **2021**,	11.7	3
213	CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	14
212	Current trends and challenges in the synthesis and applications of chitosan-based nanocomposites for plants: A review. **2021**, 261, 117904		33
211	CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects. **2021**,		
210	Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy. **2021**, 7,		5
209	Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. **2021**, 1-25		
208	Novel reporter mouse models useful for evaluating gene editing and for optimization of methods of delivering genome editing tools. **2021**, 24, 325-336		2

207	Plasmonic nanoparticles and nucleic acids hybrids for targeted gene delivery, bioimaging, and molecular recognition. **2021**, 14, 2130003		3
206	Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T1-T17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei. **2021**, 12, e0122721		3
205	Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. **2021**, 11, 217-233		3
204	Efficient Protein Transfection by Swarms of Chemically Powered Plasmonic Virus-Sized Nanorobots. **2021**,		4
203	Controlled CRISPR-Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy. **2021**, 17, e2101155		11
202	Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	12
201	Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance. **2021**, 12, 716064		5
200	delivery of CRISPR-Cas9 therapeutics: Progress and challenges. **2021**, 11, 2150-2171		17
199	Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system. **2021**,		5
198	Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
197	In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles. *Journal of Controlled Release*, **2021**, 336, 296-309	11.7	6
196	Simultaneous Stabilization and Functionalization of Gold Nanoparticles via Biomolecule Conjugation: Progress and Perspectives. *ACS Applied Materials & Interfaces*, **2021**, 13, 42311-42328	9.5	8
195	Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells. **2021**, 338, 71-80		5
194	Theranostic biomaterials for tissue engineering.. **2021**, 19,		0
193	Hearing impairment: new frontiers of regenerative medicine. **2021**, 71,		
192	Targeting of Uropathogenic Escherichia coli papG gene using CRISPR-dot nanocomplex reduced virulence of UPEC. **2021**, 11, 17801		2
191	Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A. **2021**,		0
190	Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1

189	In vivo somatic cell base editing and prime editing. *Molecular Therapy*, **2021**, 29, 3107-3124	11.7	20
188	Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. **2021**, 17, 2081-2106		12
187	Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application. *Journal of Controlled Release*, **2021**, 337, 698-717	11.7	2
186	Programming cell entry of molecules via reversible synthetic DNA circuits on cell membrane. **2021**,		1
185	Cas9 conjugate complex delivering donor DNA for efficient gene editing by homology-directed repair. **2021**, 102, 241-250		2
184	Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system. **2021**, 194, 48-55		0
183	Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing. **2021**, 8, 698521		1
182	Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. **2021**, 369, 104436		1
181	The evolution and history of gene editing technologies. **2021**, 178, 1-62		2
180	Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. **2021**, 18, 1048-1062		6
179	Polymer-Functionalized NIR-Emitting Nanoparticles: Applications in Cancer Theranostics and Treatment of Bacterial Infections. **2020**, 231-277		2
178	Engineering Functional DNA-Protein Conjugates for Biosensing, Biomedical, and Nanoassembly Applications. **2020**, 378, 41		17
177	Therapeutic Gene Editing with CRISPR: A Laboratory Medicine Perspective. **2020**, 40, 205-219		3
176	Advanced hybrid nanomaterials for biomedical applications. **2020**, 114, 100686		54
175	Gene therapy in wound healing using nanotechnology. **2021**, 29, 225-239		3
174	Correction of muscular dystrophies by CRISPR gene editing. **2020**, 130, 2766-2776		25
173	Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials. **2020**, 7, 1849543520983196		6
172	Making gene editing a therapeutic reality. **2018**, 7,		13

171	Preparation of carbon dot as a potential CRISPR/Cas9 plasmid delivery system for lung cancer cells. **2020**, 32,		5
170	On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	13
169	Nanomaterial Strategies for Delivery of Therapeutic Cargoes. 2107174		0
168	CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications. *Pharmaceutics*, **2021**, 13,	6.4	9
167	Genome engineering in rodents - status quo and perspectives. **2021**, 236772211051842		2
166	All-in-One Adeno-associated Virus Delivery and Genome Editing by Neisseria meningitidis Cas9 in vivo.		
165	CRISPR delivery particles for developing therapeutic strategies in metabolic disease.		
164	CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo.		
163	Direct purification of CRISPR/Cas ribonucleoprotein from E. coli in a single step.		
162	Introduction. **2019**, 3-12		
161	CHAPTER 17:CRISPR-based Technologies for Genome Engineering: Properties, Current Improvements and Applications in Medicine. **2019**, 400-433		1
160	Single-Cell Technologies for Cancer Therapy. **2019**, 1-84		
159	Spatial and temporal control of CRISPR/Cas9-mediated gene editing delivered via a light-triggered liposome system.		
158	The Synergy between CRISPR and Chemical Engineering. **2019**, 19, 147-171		2
157	gEL DNA, a cloning- and PCR-free method for CRISPR-based multiplexed genome editing.		
156	Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy. **2021**, 35, 643-671		1
155	Synergistic photothermal cancer immunotherapy by Cas9 ribonucleoprotein-based copper sulfide nanotherapeutic platform targeting PTPN2. **2021**, 279, 121233		9
154	Single-Cell Technologies for Cancer Therapy. **2022**, 767-850		

153	Nanoscale delivery of phytochemicals targeting CRISPR/Cas9 for cancer therapy. **2022**, 94, 153830		0
152	Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. **2021**, 12, 6267		5
151	Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. **2020**, 4, 37-42		
150	Duchenne Muscular Dystrophy (DMD) Treatment: Past and Present Perspectives.		
149	Delivery of CRISPR/Cas9 Plasmids by Cationic Gold Nanorods: Impact of the Aspect Ratio on Genome Editing and Treatment of Hepatic Fibrosis. *Chemistry of Materials*, **2021**, 33, 81-91	9.6	5
148	Precision Cas9 Genome Editing in vivo with All-in-one, Self-targeting AAV Vectors.		
147	Recent highlights and advances in cardiac gene therapy. **2019**, 28, 229-235		1
146	Nanoparticle technologies: Recent state of the art and emerging opportunities. **2022**, 3-46		2
145	Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. **2021**, 180, 114042		5
144	Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells. **2021**, 16, e0259812		1
143	A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy. **2021**, 21, 9761-9771		5
142	CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases. **2021**, 14,		2
141	Gene Therapy and Its Application in Cardiac Diseases. **2022**, 131-148		
140	CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. **2021**, 1		4
139	Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the gene.. **2022**, 27, 184-199		1
138	Current Advances Toward the Encapsulation of Cas9.. **2021**, 10, 1576-1589		1
137	An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing. **2021**, 11,		0
136	Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1. **2021**, 13, 755392		0

135	Delivery Methods for CRISPR/Cas Reagents. **2022**, 113-148		
134	Effective Genome Editing Using CRISPR-Cas9 Nanoflowers.. *Advanced Healthcare Materials*, **2022**, e2102365	10.1	0
133	A Proton-Activatable DNA-Based Nanosystem Enables Co-Delivery of CRISPR/Cas9 and DNAzyme for Combined Gene Therapy.. **2022**,		2
132	Nanoparticle-based non-viral CRISPR delivery for enhanced immunotherapy.. **2022**,		0
131	Reengineering of the CRISPR/Cas System. **2022**, 149-186		
130	CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.. **2022**, 20, 27		3
129	A Proton-Activatable DNA-Based Nanosystem Enables Co-Delivery of CRISPR/Cas9 and DNAzyme for Combined Gene Therapy. e202116569		0
128	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.. *Journal of Controlled Release*, **2022**, 342, 345-361	11.7	7
127	CRISPR/Cas9 Ribonucleoprotein-Mediated Genome and Epigenome Editing in Mammalian Cells.. **2021**, 114087		1
126	Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics.. *Pharmaceutics*, **2022**, 14,	6.4	1
125	Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.. **2022**, e1777		1
124	Drug delivery systems for RNA therapeutics.. **2022**,		30
123	Neurofibromin and suppression of tumorigenesis: beyond the GAP.. **2022**,		0
122	Advances in Delivery Mechanisms of CRISPR Gene-Editing Reagents in Plants.. *Frontiers in Genome Editing*, **2022**, 4, 830178	2.5	3
121	Non-viral delivery of the CRISPR/Cas system: DNA RNA RNP.. *Biomaterials Science*, **2022**,	7.4	2
120	Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies. **2021**, 410, 112968		4
119	Nanocarriers for Delivery of Oligonucleotides to the CNS.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
118	MOF Effectively Deliver CRISPR and Enhance Gene-Editing Efficiency via MOF's Hydrolytic Activity of Phosphate Ester Bonds. **2022**, 134992		0

117	pH-Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA.. **2022**, e2110618		4
116	Combinatorial Polycation Synthesis and Causal Machine Learning Reveal Divergent Polymer Design Rules for Effective pDNA and Ribonucleoprotein Delivery.. **2022**, 2, 428-442		3
115	CRISPR Therapeutics for Duchenne Muscular Dystrophy.. *International Journal of Molecular Sciences* , **2022**, 23,	6.3	2
114	Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery. **2022**, 435, 135116		2
113	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. **2021**, 12, 7101		6
112	CRISPR/Cas System and Stem Cell Editing: Prospects and Possibilities in Veterinary Sciences. **2021**, 323-354		0
111	Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.. **2022**, 21, 57		7
110	Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver.. *Nature Biomedical Engineering*, **2022**,	19	5
109	The Protein Interactome of a Nanoparticle Population in Whole Cytoplasm under Near-Native Conditions: A Pilot Study. 2100283		0
108	Biomaterials for Recruiting and Activating Endogenous Stem Cells in situ Tissue Regeneration.. **2022**,		1
107	Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.. **2022**, 1		0
106	Cardiovascular Disease in Duchenne Muscular Dystrophy. **2022**,		3
105	Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.. **2022**, 12, 3756		0
104	New Advances of CRISPR/Cas9 Technique and Its Application in Disease Treatment and Medicinal Plants Research.. **2022**,		
103	Nanomaterial for Skeletal Muscle Regeneration.. **2022**, 19, 253-261		0
102	Biosafety materials: ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system.. **2022**,		1
101	Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art.. **2022**, 3, 167-187		1
100	Dual role of the nasal microbiota in neurological diseases-An unignorable risk factor or a potential therapy carrier.. **2022**, 106189		0

99	Utilizing CRISPR/Cas9 Technologies for in vivo Disease Modeling and Therapy. **2022**, 93-110		
98	Nanoparticles-mediated CRISPR/Cas gene editing delivery system.. **2022**,		1
97	Current developments in gene therapy for epidermolysis bullosa.. **2022**,		1
96	Carrier strategies boost the application of CRISPR/Cas system in gene therapy. 20210081		3
95	Chitin □A Natural Bio-feedstock and Its Derivatives. **2022**, 207-233		
94	Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.. *Journal of Controlled Release*, **2022**,	11.7	1
93	Nano-assembly of a Chemically Tailored Cas9 Ribonucleoprotein for In Vivo Gene Editing and Cancer Immunotherapy. *Chemistry of Materials*, **2022**, 34, 547-561	9.6	2
92	Non-GM Genome Editing Approaches in Crops.. *Frontiers in Genome Editing*, **2021**, 3, 817279	2.5	2
91	The Coiled-Coil Forming Peptide (KVSALKE) is A Cell Penetrating Peptide that Enhances the Intracellular Delivery of Proteins. *Advanced Healthcare Materials*, **2021**, e2102118	10.1	0
90	Self-Assembled Oligo-Urethane Nanoparticles: Their Characterization and Use for the Delivery of Active Biomolecules into Mammalian Cells. *ACS Applied Materials & Interfaces*, **2021**,	9.5	1
89	CRISPR/Cas9-Mediated Allele-Specific Disruption of a Dominant Pathogenic Variant Improves Collagen VI Network in Patient Fibroblasts.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
88	CRISPR-Click Enables Dual-Gene Editing with Modular Synthetic sgRNAs.. *Bioconjugate Chemistry*, **2022**,	6.3	0
87	CRISPR-Cas Technology a New Era in Genomic Engineering. *Biotechnology Reports (Amsterdam, Netherlands)*, **2022**, e00731	5.3	0
86	Nano-vectors for CRISPR/Cas9-mediated genome editing. *Nano Today*, **2022**, 44, 101482	17.9	2
85	Table_1.XLSX. **2020**,		
84	Table_2.XLSX. **2020**,		
83	A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review.. *Frontiers in Bioengineering and Biotechnology*, **2022**, 10, 833833	5.8	0
82	??????[12]aneN₃????????????????. *Chinese Science Bulletin* , **2022**,	2.9	0

81	Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells. *Biomedicine and Pharmacotherapy*, **2022**, 150, 113027	7.5	
80	Polyrotaxane-based multi-step transformable materials for the delivery of Cas9 ribonucleoprotein. *Applied Materials Today*, **2022**, 27, 101488	6.6	1
79	Intramuscular delivery of neural crest stem cell spheroids enhances neuromuscular regeneration after denervation injury.. *Stem Cell Research and Therapy*, **2022**, 13, 205	8.3	1
78	Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview. *Biomaterials Science*,	7.4	0
77	Inner Ear Drug Delivery for Sensorineural Hearing Loss: Current Challenges and Opportunities. *Frontiers in Neuroscience*, **2022**, 16,	5.1	1
76	Targeted Therapeutics for Rare Disorders. **2022**,		
75	CRISPR-Cas-Based Gene Therapy to Target Viral Infections. **2022**, 85-125		0
74	Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene. *Molecular Therapy*, **2022**,	11.7	3
73	Opportunity and challenges for nanotechnology application for genome editing in plants. **2022**, 1, 100001		1
72	Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. *Cells*, **2022**, 11, 1843	7.9	2
71	Transient, DNA-free in vivo CRISPR/Cas9 genome edition for flexible modelling of endometrial carcinogenesis.		
70	CRISPR Modeling and Correction of Cardiovascular Disease. *Circulation Research*, **2022**, 130, 1827-1850	15.7	4
69	CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson Disease. *Pharmaceutics*, **2022**, 14, 1252	6.4	2
68	Cas-Based Systems for RNA Editing in Gene Therapy of Monogenic Diseases: In Vitro and in Vivo Application and Translational Potential. *Frontiers in Cell and Developmental Biology*, 10,	5.7	1
67	Novel Nanotechnology-Based Vector Delivery in CRISPR System for Transgene-Free Editing. **2022**, 279-294		
66	Multiorgans-on-a-Chip for Personalized Medicine. **2022**, 289-324		
65	CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. *International Immunopharmacology*, **2022**, 110, 109041	5.8	1
64	Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems. **2022**, 12, 371-391		1

63	The Promising Nanovectors for Gene Delivery in Plant Genome Engineering. **2022**, 23, 8501	1
62	CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.	0
61	Chitosan-Based Nanocomposites for Biological Applications.	0
60	Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. **2022**, 20,	3
59	Rational Molecular Engineering of Organic Semiconducting Nanoplatforms for Advancing NIR-II Fluorescence Theranostics. 2201067	1
58	Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead. **2022**, 931, 175173	0
57	CRISPR-Cas9 based non-viral approaches in nanoparticle elicited therapeutic delivery. **2022**, 76, 103737	0
56	Genome editing in cancer: Challenges and potential opportunities. **2023**, 21, 394-402	0
55	Genome Editing in Crops Via Homology-Directed Repair Using a Geminivirus-Based CRISPR/Cas9 System. **2022**, 119-137	0
54	Cationic lipopolymeric nanoplexes containing the CRISPR/Cas9 ribonucleoprotein for genome surgery. **2022**, 10, 7634-7649	0
53	Applications of Nanotechnology in Preservation and Development of the Plants: A Look Back. **2022**, 121-140	0
52	CRISPR/Cas9 system: a reliable and facile genome editing tool in modern biology.	0
51	The horizon of pediatric cardiac critical care. 10,	0
50	Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. 10,	0
49	CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives. **2022**, 11, 2964	0
48	Integrating Micro and Nano Technologies for Cell Engineering and Analysis: Toward the Next Generation of Cell Therapy Workflows.	0
47	Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. **2022**, 14, 1842	0
46	Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease. **2022**, 229-258	0

45	Genome Editing advances in Soybean Improvement against Biotic and Abiotic Stresses. **2022**, 241-274	0
44	CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy. **2022**, 27-64	0
43	Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.	1
42	Nanomedicine for Treating Muscle Dystrophies: Opportunities, Challenges, and Future Perspectives. **2022**, 23, 12039	0
41	Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies. **2022**, 20,	0
40	CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. **2022**, 3,	1
39	Gold Nanoparticle-Mediated Gene Therapy. **2022**, 14, 5366	0
38	Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases. 4,	0
37	In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. **2022**, 291, 121876	1
36	Homology-Directed Repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy.	0
35	Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses. **2022**, 191, 114616	0
34	Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. **2023**, 192, 114636	0
33	CRISPR/Cas systems: Delivery and application in gene therapy. 10,	0
32	Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.	0
31	CRISPR-Based Tools for Fighting Rare Diseases. **2022**, 12, 1968	0
30	Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective. **2023**, 315-339	0
29	Massively Parallel CRISPR-Based Genetic Perturbation Screening at Single-Cell Resolution. 2204484	0
28	Intelligent nanotherapeutic strategies for the delivery of CRISPR system. **2022**,	0

27	Genome Editing and Pathological Cardiac Hypertrophy. **2023**, 87-101	0
26	Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities. **2022**, 20,	3
25	Genome Editing in Dyslipidemia and Atherosclerosis. **2023**, 139-156	0
24	Endosomal Escapable and Nuclear Localizing Cationic Polyaspartate-Based CRISPR Activation System for Preventing Respiratory Virus Infection by Specifically Inducing Interferon-**2022**, 14, 55376-55391	0
23	Biological and genetic therapies for the treatment of Duchenne muscular dystrophy. 1-11	0
22	Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical appliances: Current insights and perspectives. **2022**, 224, 111415	0
21	Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. **2023**, 14,	2
20	A CRISPR-Cas Cure for HIV/AIDS. **2023**, 24, 1563	0
19	Integration of DNA barcoding and nanotechnology in drug delivery. **2023**, 123262	0
18	Metal Nanoparticles: Synthesis, Characterization, and Biomedical Applications. **2023**, 85-102	0
17	Nucleic acid nanostructure for delivery of CRISPR/Cas9-based gene editing system.	0
16	Clinical progress in genome-editing technology and in vivo delivery techniques. **2023**,	0
15	CRISPR technology: A decade of genome editing is only the beginning. **2023**, 379,	4
14	Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context. **2023**, 37, 181-203	1
13	Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy. **2023**, 15,	0
12	Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy.	0
11	Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles. **2023**, 15, 10464-10476	0
10	Delivery challenges for CRISPR Cas9 genome editing for Duchenne muscular dystrophy. **2023**, 4, 011307	0

9	Silk-Gel Powered Adenoviral Vector Enables Robust Genome Editing of PD-L1 to Augment Immunotherapy across Multiple Tumor Models. 2206399	0
8	New CRISPR Technology for Creating Cell Models of Lipoprotein Assembly and Secretion.	0
7	The CRISPR/Cas9 System Delivered by Extracellular Vesicles. **2023**, 15, 984	0
6	Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing. **2023**, 13, 1500-1519	0
5	Nanoarchitectures to Deliver Nucleic Acid Drugs to Disease Sites.	0
4	Nanotechnology-enabled gene delivery for cancer and other genetic diseases. 1-18	0
3	Vector enabled CRISPR gene editing □A revolutionary strategy for targeting the diversity of brain pathologies. **2023**, 487, 215172	0
2	Mechanisms of the Specificity of the CRISPR/Cas9 System in Genome Editing. **2023**, 57, 258-271	0
1	Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor. **2023**, 298, 122133	0